ライフサイエンスコーパス: pulmonary arterial hypertension

1 ental to well-validated prognostic scores in pulmonary arterial hypertension.

2 Cpc-PH bears similarities to pulmonary arterial hypertension.

3 roducible prognostic marker in patients with pulmonary arterial hypertension.

4 tan is beneficial for long-term treatment of pulmonary arterial hypertension.

5 monotherapy in patients with newly diagnosed pulmonary arterial hypertension.

6 as heart failure, arterial hypertension, and pulmonary arterial hypertension.

7 e, chronic obstructive pulmonary disease, or pulmonary arterial hypertension.

8 ents known to be effective in other forms of pulmonary arterial hypertension.

9 0.03 mg/kg, in the rat moncrotaline model of pulmonary arterial hypertension.

10 oth muscle cell survival patterns to promote pulmonary arterial hypertension.

11 e progression-free survival of patients with pulmonary arterial hypertension.

12 cular disorders, including heart failure and pulmonary arterial hypertension.

13 a is a critical regulator of hypoxia-induced pulmonary arterial hypertension.

14 s, including cancer, kidney nephropathy, and pulmonary arterial hypertension.

15 ich is currently used to treat patients with pulmonary arterial hypertension.

16 of a new treatment option for patients with pulmonary arterial hypertension.

17 pathology, compared with other patients with pulmonary arterial hypertension.

18 FNA1 may underlie vulnerability to injury in pulmonary arterial hypertension.

19 ole cohort, and 89 and 85% for patients with pulmonary arterial hypertension.

20 ssels and plexiform lesions of patients with pulmonary arterial hypertension.

21 related with skin and lung fibrosis and with pulmonary arterial hypertension.

22 nction (PED) has been described in HF and in pulmonary arterial hypertension.

23 ll patients during the trial and no signs of pulmonary arterial hypertension.

24 is, acute respiratory distress syndrome, and pulmonary arterial hypertension.

25 iation studies (GWAS) and a meta-analysis of pulmonary arterial hypertension.

26 fib in RV fibrosis in human and experimental pulmonary arterial hypertension.

27 nd cocaine leading to the development of HIV-pulmonary arterial hypertension.

28 gonists have revolutionized the treatment of pulmonary arterial hypertension.

29 the class II MHC region were associated with pulmonary arterial hypertension.

30 tion in diseases such as atherosclerosis and pulmonary arterial hypertension.

31 (64%) were receiving background therapy for pulmonary arterial hypertension.

32 OX17 and in HLA-DPA1/DPB1 is associated with pulmonary arterial hypertension.

33 , with no observed valvular heart disease or pulmonary arterial hypertension.

34 r operating characteristic curve of 0.94 for pulmonary arterial hypertension, 0.91 for hypertrophic c

35 ts who died (28/37) had idiopathic/heritable pulmonary arterial hypertension (76% versus 33% overall)

36 cts 63%, pulmonary alveolar proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts

37 ific medications enrolled in the Imatinib in Pulmonary Arterial Hypertension, a Randomized Efficacy S

38 e Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION) trial.

39 atients with pulmonary hypertension (31 with pulmonary arterial hypertension and 26 with chronic thro

40 lmonary adventitia of humans with idiopathic pulmonary arterial hypertension and animals with PH and

41 mia is prevalent in patients with idiopathic pulmonary arterial hypertension and associated with redu

42 ortant role in various pathologies including pulmonary arterial hypertension and cardiomyopathy.

43 were associated with poor survival for both pulmonary arterial hypertension and chronic thromboembol

44 s with pressure-overloaded RVs of idiopathic pulmonary arterial hypertension and chronic thromboembol

45 In idiopathic pulmonary arterial hypertension and chronic thromboembol

46 inical evidence of RV fibrosis in idiopathic pulmonary arterial hypertension and chronic thromboembol

47 The hyperproliferative ECs of human pulmonary arterial hypertension and glioblastoma multifo

48 tor antagonists are in clinical use to treat pulmonary arterial hypertension and have been under clin

49 as downregulated in patients with idiopathic pulmonary arterial hypertension and in rats treated with

50 nsibility is reduced in patients with HF and pulmonary arterial hypertension and is closely related t

51 rtant features leading to RV lipotoxicity in pulmonary arterial hypertension and may point to novel a

52 ung tissue and serum from both patients with pulmonary arterial hypertension and rodents with PH.

53 In patients with pulmonary arterial hypertension and RV failure, RVfib ha

54 erial smooth muscle cells from patients with pulmonary arterial hypertension and that EYA3 tyrosine p

55 tion is common to heritable and nonheritable pulmonary arterial hypertension and to experimental pulm

56 related pathologies (valvular heart disease, pulmonary arterial hypertension) and is an off target of

57 clerosis, angiogenesis, intimal hyperplasia, pulmonary arterial hypertension, and cardiac hypertrophy

58 long-term use of riociguat in patients with pulmonary arterial hypertension, and emphasise the progn

59 ecapillary pulmonary hypertension because of pulmonary arterial hypertension, and in patients with po

60 terial hypertension, rats with Sugen/hypoxia-pulmonary arterial hypertension, and mice exposed to chr

61 scular necrosis, severe splenic dysfunction, pulmonary arterial hypertension, and sepsis, which may r

62 n focus on World Health Organization group 1 pulmonary arterial hypertension, and the efficacy of man

63 ways that are central to the pathogenesis of pulmonary arterial hypertension are reviewed, including

64 lafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.

65 boembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar.

66 has been previously genetically linked with pulmonary arterial hypertension, as a major component of

67 n human clinical trials for the treatment of pulmonary arterial hypertension, as well as other cardio

68 peutic strategies to treat heart failure and pulmonary arterial hypertension, as well as those that t

69 Pulmonary arterial hypertension associated with congenit

70 specially in younger children and those with pulmonary arterial hypertension associated with congenit

71 on profiles in the sera of the patients with pulmonary arterial hypertension associated with congenit

72 gnaling is implicated in the pathogenesis of pulmonary arterial hypertension, based in part on the ab

73 3 were increased in patients with idiopathic pulmonary arterial hypertension but did not correlate wi

74 ) is a feature of endothelial dysfunction in pulmonary arterial hypertension, but its role in disease

75 Rare genetic variants cause pulmonary arterial hypertension, but the contribution of

76 get whose function in the pathophysiology of pulmonary arterial hypertension can be targeted by avail

77 t common forms of pulmonary hypertension are pulmonary arterial hypertension, chronic thromboembolic

78 from patients with idiopathic and heritable pulmonary arterial hypertension compared with control su

79 the established prognostic risk equation for pulmonary arterial hypertension derived from the REVEAL

80 e disease, such as scleroderma renal crisis, pulmonary arterial hypertension, digital ulceration, and

81 site of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or

82 ing costs for the planning of a hypothetical pulmonary arterial hypertension drug trial using imaging

83 Idiopathic and heritable pulmonary arterial hypertension form a rare but molecula

84 In familial pulmonary arterial hypertension (FPAH), the autosomal do

85 rolled patients with idiopathic or heritable pulmonary arterial hypertension from London (UK; cohorts

86 PV distensibility was lowest in the pulmonary arterial hypertension group (0.40+/-0.24% per

87 The treatment of pulmonary arterial hypertension has advanced substantial

88 investigate survival in a rare disease like pulmonary arterial hypertension has considerable ethical

89 Hereditary pulmonary arterial hypertension (HPAH) is a rare, fatal

90 I receptor (BMPR-II) gene underlie heritable pulmonary arterial hypertension (HPAH).

91 me, and mitral annulus e-prime) and disease (pulmonary arterial hypertension, hypertrophic cardiomyop

92 aired samples from 43 incident patients with pulmonary arterial hypertension in cohort 3 (p=0.0133).

93 in 93 patients with idiopathic or heritable pulmonary arterial hypertension in cohort 4, with 4.4 ye

94 We tested for genome-wide association for pulmonary arterial hypertension in large international c

95 pulmonary disease patients and less cases of pulmonary arterial hypertension in NS group.

96 clinical trials have evaluated therapies for pulmonary arterial hypertension in patients with portopu

97 POPH is characterized by development of pulmonary arterial hypertension in the setting of portal

98 was incremental to risk prediction scores in pulmonary arterial hypertension, including the Registry

99 is a strong prognostic marker in idiopathic pulmonary arterial hypertension, independent of invasive

100 In treatment-naive patients with pulmonary arterial hypertension, initial combination the

101 Idiopathic pulmonary arterial hypertension (IPAH) is a cardiopulmon

102 Idiopathic pulmonary arterial hypertension (IPAH) is usually withou

103 from pulmonary arteries (PAAF) of idiopathic pulmonary arterial hypertension (IPAH) patients and heal

104 higher in PAE cells isolated from idiopathic pulmonary arterial hypertension (IPAH) patients compared

105 anticoagulation is recommended in idiopathic pulmonary arterial hypertension (IPAH).

106 een recommended for patients with idiopathic pulmonary arterial hypertension (IPAH).

107 fied as pre-capillary (as seen in idiopathic pulmonary arterial hypertension [IPAH]) or post-capillar

108 Pulmonary arterial hypertension is a chronic disease ass

109 Pulmonary arterial hypertension is a devastating disease

110 Pulmonary arterial hypertension is a progressive disorde

111 Pulmonary arterial hypertension is a severe lethal cardi

112 Pulmonary arterial hypertension is characterized by endo

113 Pulmonary arterial hypertension is characterized by endo

114 RATIONALE: Idiopathic or heritable pulmonary arterial hypertension is characterized by loss

115 Pulmonary arterial hypertension is characterized by vasc

116 The incidence of pulmonary arterial hypertension is greater in women, sug

117 entifying predictors of long-term outcome in pulmonary arterial hypertension is important to assess d

118 ular (RV) pressure overload in patients with pulmonary arterial hypertension is unknown.

119 iver of (chronic) human disorders, including pulmonary arterial hypertension, kidney disease, and ath

120 ality included an etiologic group other than pulmonary arterial hypertension (P < 0.001), age at diag

121 Idiopathic pulmonary arterial hypertension (PAH [IPAH]) is an insid

122 Pulmonary arterial hypertension (PAH) affects ~15-50 peo

123 nary arterial and venous compartments, as in pulmonary arterial hypertension (PAH) and pulmonary veno

124 mulating evidence implicates inflammation in pulmonary arterial hypertension (PAH) and therapies targ

125 ad undergone Fontan procedure, patients with pulmonary arterial hypertension (PAH) and two groups of

126 l efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are described.

127 hanisms of right ventricular (RV) failure in pulmonary arterial hypertension (PAH) are poorly underst

128 Rationale: Idiopathic and heritable pulmonary arterial hypertension (PAH) are rare but compr

129 Although proinflammatory processes in PH and pulmonary arterial hypertension (PAH) are the focus of e

130 ast, limited data support anticoagulation in pulmonary arterial hypertension (PAH) associated with sy

131 artery in control subjects and patients with pulmonary arterial hypertension (PAH) at rest.

132 onsistently been associated with survival in pulmonary arterial hypertension (PAH) at the time of dia

133 enetic basis for heritable predisposition to pulmonary arterial hypertension (PAH) has altered the cl

134 of cardiovascular risk, however, its role in pulmonary arterial hypertension (PAH) has not been deter

135 kground - Approximately 25% of patients with pulmonary arterial hypertension (PAH) have been found to

136 s the pulmonary phenotype and BPD-associated pulmonary arterial hypertension (PAH) in BPD mouse model

137 lls (PAECs) from patients who had idiopathic pulmonary arterial hypertension (PAH) in comparison with

138 ssure in healthy individuals and exacerbates pulmonary arterial hypertension (PAH) in patients, even

139 ons are hallmarks of the pathology of severe pulmonary arterial hypertension (PAH) in patients.

140 rvival and treatment strategies in pediatric pulmonary arterial hypertension (PAH) in the current era

141 r system, to seek evidence for alteration in pulmonary arterial hypertension (PAH) in which apelin si

142 The vascular remodeling responsible for pulmonary arterial hypertension (PAH) involves predomina

143 Pulmonary arterial hypertension (PAH) is a cardiopulmona

144 Rationale: Pulmonary arterial hypertension (PAH) is a degenerative

145 Pulmonary arterial hypertension (PAH) is a devastating c

146 Pulmonary arterial hypertension (PAH) is a devastating d

147 Pulmonary arterial hypertension (PAH) is a disease chara

148 Pulmonary arterial hypertension (PAH) is a fatal conditi

149 Pulmonary arterial hypertension (PAH) is a fatal disease

150 Pulmonary arterial hypertension (PAH) is a fatal disease

151 Pulmonary arterial hypertension (PAH) is a heterogeneous

152 Pulmonary arterial hypertension (PAH) is a lethal vascul

153 Rationale: Pulmonary arterial hypertension (PAH) is a life-shorteni

154 Pulmonary arterial hypertension (PAH) is a life-threaten

155 Heterogeneity in response to treatment of pulmonary arterial hypertension (PAH) is a major challen

156 Pulmonary arterial hypertension (PAH) is a medically inc

157 Pulmonary arterial hypertension (PAH) is a progressive d

158 Pulmonary arterial hypertension (PAH) is a progressive l

159 Pulmonary arterial hypertension (PAH) is a proliferative

160 Pulmonary arterial hypertension (PAH) is a rare and dead

161 Pulmonary arterial hypertension (PAH) is a rare but fata

162 Pulmonary arterial hypertension (PAH) is a rare cardiopu

163 Pulmonary arterial hypertension (PAH) is a rare disease

164 Pulmonary arterial hypertension (PAH) is a rare, fatal,

165 Pulmonary arterial hypertension (PAH) is a rare, progres

166 Pulmonary arterial hypertension (PAH) is a serious lung

167 Pulmonary arterial hypertension (PAH) is a severe disord

168 Pulmonary arterial hypertension (PAH) is a vascular remo

169 Pulmonary arterial hypertension (PAH) is a vasculopathy

170 RATIONALE: Pulmonary arterial hypertension (PAH) is an obstructive

171 Pulmonary arterial hypertension (PAH) is an obstructive

172 Pulmonary arterial hypertension (PAH) is an often fatal

173 Pulmonary arterial hypertension (PAH) is an uncommon dis

174 Pulmonary arterial hypertension (PAH) is characterized b

175 Pulmonary arterial hypertension (PAH) is characterized b

176 Importance: Pulmonary arterial hypertension (PAH) is characterized b

177 Pulmonary arterial hypertension (PAH) is characterized b

178 Pulmonary arterial hypertension (PAH) is characterized b

179 Rationale: Pulmonary arterial hypertension (PAH) is characterized b

180 Pulmonary arterial hypertension (PAH) is characterized b

181 Pulmonary arterial hypertension (PAH) is characterized b

182 Pulmonary arterial hypertension (PAH) is commonly associ

183 nce-based treatment guidelines for pediatric pulmonary arterial hypertension (PAH) is hampered by lac

184 severity and predicting outcome in pediatric pulmonary arterial hypertension (PAH) is insufficiently

185 Pulmonary Arterial Hypertension (PAH) is overrepresented

186 alterations of the pulmonary vasculature in pulmonary arterial hypertension (PAH) is primarily provi

187 eraction contributes to small vessel loss in pulmonary arterial hypertension (PAH) is unclear.

188 , but its efficacy in treating patients with pulmonary arterial hypertension (PAH) is unknown.

189 curately predicting and testing the types of Pulmonary arterial hypertension (PAH) of each patient us

190 multiparametric risk assessment approach for pulmonary arterial hypertension (PAH) outlined in PAH gu

191 ndothelial cells (hPAECs) is associated with pulmonary arterial hypertension (PAH) progression and pu

192 Pulmonary arterial hypertension (PAH) remains a concern

193 lure, but whether it would be beneficial for pulmonary arterial hypertension (PAH) remains to be expl

194 pies for pulmonary vascular diseases such as pulmonary arterial hypertension (PAH) remains unknown.

195 topulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH) that can develop a

196 n linked to occlusive vascular remodeling in pulmonary arterial hypertension (PAH) that is hereditary

197 Murine models of pulmonary arterial hypertension (PAH) that recapitulate

198 e the main genetic risk factor for heritable pulmonary arterial hypertension (PAH) with incomplete pe

199 cially true with animal models used to study pulmonary arterial hypertension (PAH), a disease with tw

200 The etiology of schistosomiasis-associated pulmonary arterial hypertension (PAH), a major cause of

201 BMP receptor BMPR2 are the leading cause of pulmonary arterial hypertension (PAH), a rare disease of

202 In pulmonary arterial hypertension (PAH), acute vasodilator

203 function (LVSD), diastolic dysfunction (DD), pulmonary arterial hypertension (PAH), and increased lef

204 the role of female sex and estradiol (E2) in pulmonary arterial hypertension (PAH), but it is not kno

205 mutations in the CAV1 gene in patients with pulmonary arterial hypertension (PAH), but the mechanism

206 e linked to progressive small vessel loss in pulmonary arterial hypertension (PAH), but the molecular

207 ng evidence that microRNAs are implicated in pulmonary arterial hypertension (PAH), but underlying me

208 lecular abnormalities have been described in pulmonary arterial hypertension (PAH), complicating the

209 levels of aldosterone activate Akt, and, in pulmonary arterial hypertension (PAH), correlate with pu

210 In pulmonary arterial hypertension (PAH), endothelial dysfu

211 plays a central role in the pathogenesis of pulmonary arterial hypertension (PAH), promoting vasocon

212 surements in the management of children with pulmonary arterial hypertension (PAH), we assessed growt

213 Another is pulmonary arterial hypertension (PAH), where gravitation

214 and hemodynamic characteristics, response to pulmonary arterial hypertension (PAH)-approved drugs, an

215 Importance: Recent trends and outcomes of pulmonary arterial hypertension (PAH)-related hospitaliz

216 reasingly recognized as a cause of angina in pulmonary arterial hypertension (PAH).

217 atients and defining treatment strategies in pulmonary arterial hypertension (PAH).

218 ated with negative outcomes in children with pulmonary arterial hypertension (PAH).

219 s been identified in a family with heritable pulmonary arterial hypertension (PAH).

220 Here, we address this in pulmonary arterial hypertension (PAH).

221 s been identified in a family with heritable pulmonary arterial hypertension (PAH).

222 racteristic hallmarks in the pathogenesis of pulmonary arterial hypertension (PAH).

223 eceptor type 2 mutation-associated heritable pulmonary arterial hypertension (PAH).

224 ed in some patients suffering from heritable pulmonary arterial hypertension (PAH).

225 4 inactivation confers a survival benefit in pulmonary arterial hypertension (PAH).

226 mponents of pulmonary vascular remodeling in pulmonary arterial hypertension (PAH).

227 onal capacity and prognosis in patients with pulmonary arterial hypertension (PAH).

228 ons in GDF2 were identified in patients with pulmonary arterial hypertension (PAH).

229 r if Cpc-PH shares molecular similarities to pulmonary arterial hypertension (PAH).

230 I (BMPR2) are the commonest genetic cause of pulmonary arterial hypertension (PAH).

231 proliferation, leading to the development of pulmonary arterial hypertension (PAH).

232 sure is an established prognostic measure in pulmonary arterial hypertension (PAH).

233 cell (PASMC) phenotype and are implicated in pulmonary arterial hypertension (PAH).

234 long-term therapeutics for the treatment of pulmonary arterial hypertension (PAH).

235 on are considered two primary instigators of pulmonary arterial hypertension (PAH).

236 nt factor of both morbidity and mortality in pulmonary arterial hypertension (PAH).

237 n the endothelium as an initiating factor in pulmonary arterial hypertension (PAH).

238 Schistosomiasis is a major cause of pulmonary arterial hypertension (PAH).

239 endothelial cells (ECs) contribute to severe pulmonary arterial hypertension (PAH).

240 pulmonary vascular remodeling in idiopathic pulmonary arterial hypertension (PAH).

241 in the evaluation and care of patients with pulmonary arterial hypertension (PAH).

242 y hypertension and in the lungs of rats with pulmonary arterial hypertension (PAH).

243 EC) are mechanistically linked to origins of pulmonary arterial hypertension (PAH).

244 ascular diseases such as atherosclerosis and pulmonary arterial hypertension (PAH).

245 quiescence factor with protective effects in pulmonary arterial hypertension (PAH).

246 ve for the intravenous and oral treatment of pulmonary arterial hypertension (PAH).

247 a possible disease-causing gene in heritable pulmonary arterial hypertension (PAH).

248 is available on racial/ethnic differences in pulmonary arterial hypertension (PAH).Objectives: Determ

249 Females are predisposed to pulmonary arterial hypertension (PAH); evidence suggests

250 Healthy controls (n=10) and children with pulmonary arterial hypertension (PAH; n=10) and repaired

251 hat KCNK3 loss of function is a key event in pulmonary arterial hypertension pathogenesis.

252 e findings, relative to controls, lungs from pulmonary arterial hypertension patients displayed a sig

253 endothelial cells derived from controls and pulmonary arterial hypertension patients indicate that B

254 In lung from pulmonary arterial hypertension patients, PW1-expressing

255 tifier K(+) channel, have been identified in pulmonary arterial hypertension patients.

256 cal differences similar to those observed in pulmonary arterial hypertension patients.

257 ypoxia-induced PH and humans with idiopathic pulmonary arterial hypertension (PH-Fibs) displayed aero

258 l (Prostacyclin [PGI(2)] Receptor Agonist In Pulmonary Arterial Hypertension) provides an opportunity

259 Patients with pulmonary arterial hypertension, rats with Sugen/hypoxia

260 ters and long-term outcomes in patients with pulmonary arterial hypertension receiving riociguat in t

261 Pulmonary arterial hypertension risk variants determined

262 had two independent signals associated with pulmonary arterial hypertension (rs13266183, 1.36 [1.25-

263 MCT rats developed pulmonary arterial hypertension, RV fibrosis, and RV fai

264 Patients with hemodynamics of pulmonary arterial hypertension should be referred to sp

265 Patients requiring additional pulmonary arterial hypertension-specific therapy discont

266 Scleroderma-associated pulmonary arterial hypertension (SSc-PAH) is a rare dise

267 lates positively with vascular remodeling in pulmonary arterial hypertension, suggesting that aldoste

268 ates of mortality were bridging therapy with pulmonary arterial hypertension-targeted drugs, postoper

269 n pulmonary endarterectomy is not an option, pulmonary arterial hypertension-targeted pharmacotherapy

270 an attainable goal using the combination of pulmonary arterial hypertension-targeted therapies and L

271 rformed in 35 patients who were treated with pulmonary arterial hypertension-targeted therapies befor

272 In both operated and not-operated patients, pulmonary arterial hypertension-targeted therapy did not

273 nt of SOX17 function might be more common in pulmonary arterial hypertension than suggested by rare m

274 imatinib, 2 putative treatments explored for pulmonary arterial hypertension that target aerobic glyc

275 placebo, 62% of whom were taking background pulmonary arterial hypertension therapy, tended to be lo

276 dy with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outc

277 val in patients with idiopathic or heritable pulmonary arterial hypertension to improve risk stratifi

278 e same patients with idiopathic or heritable pulmonary arterial hypertension, to determine whether th

279 tured from lungs of patients with idiopathic pulmonary arterial hypertension versus control subjects

280 lly occurring amino acid and a biomarker for pulmonary arterial hypertension was selected as the best

281 ol subjects and six patients with idiopathic pulmonary arterial hypertension were analyzed.

282 tal, 95 patients with idiopathic or familial pulmonary arterial hypertension were genetically screene

283 ODS AND From 2005 to 2014, 228 patients with pulmonary arterial hypertension were prospectively enrol

284 tudy, in which treatment-naive patients with pulmonary arterial hypertension were randomly assigned i

285 useful for risk stratification in idiopathic pulmonary arterial hypertension, whereas it has not been

286 signaling mutations have been implicated in pulmonary arterial hypertension, whereas the role of TGF

287 ation functional class II or III symptoms of pulmonary arterial hypertension who had not previously r

288 Among participants with pulmonary arterial hypertension who had not received pre

289 dy population consisted of 605 patients with pulmonary arterial hypertension who were randomly assign

290 cutive patients with idiopathic or heritable pulmonary arterial hypertension with 2 years' follow-up

291 entan has demonstrated long-term efficacy in pulmonary arterial hypertension with a good hepatic safe

292 irculating proteins identifies patients with pulmonary arterial hypertension with a high risk of mort

293 nvestigated RV function in patients who have pulmonary arterial hypertension with and without the BMP

294 nilotinib and particularly ponatinib and of pulmonary arterial hypertension with dasatinib have rais

295 In heritable pulmonary arterial hypertension with germline mutation i

296 practical application in progressive/severe pulmonary arterial hypertension with inadequate response

297 We used a transgenic mouse model of pulmonary arterial hypertension with mutant BMPR2 and ge

298 ian survival from diagnosis in patients with pulmonary arterial hypertension with the C/C homozygous

299 agnetic resonance measurements in idiopathic pulmonary arterial hypertension, with no studies investi

300 ), HF with reduced ejection fraction (n=55), pulmonary arterial hypertension without left heart failu